Company executives said they estimated 2023 would be a transition year as the company pivots to a commercial market instead of a government market.
Related posts:
Biden shakes up vaccine strategy as he sets new goal
Pfizer seeks full FDA approval of its Covid-19 vaccine
Covid response chief has no regrets on Johnson & Johnson pause
How Covid data gaps allowed Delta to proliferate
Chicago mayor tests positive for Covid a day after announcing school reopening deal
Abortion statistics by state: Maps, trigger laws, and possible bans
Vaccine injury compensation programs overwhelmed as congressional reform languishes
Can long Covid lead to death? A new analysis suggests it could
FDA advisers vote to recommend Novavax Covid-19 vaccine
6 charts that show how money and influence shaped the world’s Covid plan
Biden’s monkeypox adviser is managing a virus alongside conservative fascination in his Instagram feed
FDA expert vaccine advisers recommend change to Covid shot formulation
